CTOs on the Move

Invicro

www.invicro.com

 
Invicro, A Konica Minolta Company, was founded with a mission of improving the role and function of imaging in translational drug discovery and development. To this effort we offer a suite of services and software with applications ranging from tissue to human, from target identification to Phase IV trials across the entire electromagnetic spectrum of imaging techniques. We start all projects with a data-driven mentality and the knowledge that quality data are the key to solving scientific challenges. Our analytics team is constantly innovating to develop the processes by which true and valuable quantitative information is extracted. Our approach has ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.invicro.com
  • 100 College Street 9th Floor
    New Haven, CT USA 06510
  • Phone: 617.904.2100

Executives

Name Title Contact Details
Timothy Moran
Senior Director of Product Management Profile
Chris Fuller
Vice President of Software Profile

Similar Companies

Epigentek

Epigentek is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Boston Immune Technologies and Therapeutics

Boston Immune Technologies & Therapeutics based Inc

Westbridge Agricultural Products

Through safe agricultural, home and garden products and technologies, Westbridge is cultivating environmental awareness.

Aruvant

Aruvant`s mission is to bring hope to patients living with rare diseases by developing life changing and potentially curative gene therapies, with a near-term focus on sickle cell disease. Aruvant is a part of the Roivant family of companies. We have a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. We have an active research program with a lead product candidate in development for individuals suffering from sickle cell disease (SCD). Our lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is currently in a clinical trial as a potential one-time curative treatment for SCD. Preliminary clinical data from the ongoing Phase 1/2 study demonstrated durable efficacy in reducing the negative impacts of SCD. We are preparing for the launch of our pivotal clinical trial in SCD. We continue to look for new people to add to our talented team.

Loyal

Loyal is part of Cellular Longevity, a company working to develop the first drugs explicitly intended to extend healthspan and lifespan — first in dogs, and then in humans, too. By quantifying and controlling the mechanisms of aging, we hope to delay the onset and reduce the severity of age-related diseases, which means more, healthier years for both species. At Loyal, our first products to market are focused on longevity and healthspan in dogs. Join us in our mission to help dogs everywhere.